Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Gallbladder Disease on Ozempic (Semaglutide 0.5-2 mg): Week-by-Week Timeline of What to Expect

By
Published Updated Last reviewed
7 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Label warning / Acute gallbladder disease is a warned risk on the Ozempic label [1]
  • Label action / If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1]
  • Label trial rates / Cholelithiasis 1.5% on 0.5 mg, 0.4% on 1 mg, none on placebo [1]
  • Postmarketing reports / Cholecystitis and cholecystectomy are listed; frequency cannot be estimated [1]
  • SELECT (2.4 mg, no diabetes) / Gallbladder-related disorders 2.8% vs 2.3% placebo [2]
  • Pooled semaglutide trials / Cholelithiasis odds ratio 2.06 vs placebo [3]
  • GLP-1 meta-analysis / Gallbladder disorders 26% higher than controls [4]
  • Ozempic titration / 0.25 mg for 4 weeks, then 0.5 mg; 1 mg and 2 mg only after at least 4 weeks at the previous dose [1]

Is there a week-by-week timeline for gallbladder disease on Ozempic?

The gallbladder results available are whole-study totals, not a week-by-week timeline. One semaglutide 2.4 mg trial ran for 68 weeks [5], while SELECT had a mean follow-up of 39.8 months [6]. A broader GLP-1 drug analysis had a mean follow-up of 2.4 years [4].

What the Ozempic label says

The Ozempic label gives acute gallbladder disease its own warning item: if cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1]. Cholecystitis and cholecystectomy also appear among the label's postmarketing reports, where frequency cannot be estimated [1].

The label states that in placebo-controlled trials cholelithiasis was reported in 1.5% of patients treated with Ozempic 0.5 mg and 0.4% treated with 1 mg, and was not reported in placebo-treated patients [1]. These are whole-trial rates with no breakdown by week. The label's main adverse reaction table, from two placebo-controlled trials in type 2 diabetes (mean exposure to Ozempic 32.9 weeks), lists only nausea, vomiting, diarrhea, abdominal pain and constipation at 5% or more [1].

What the numbers are

Apart from the label's rates for 0.5 mg and 1 mg, the gallbladder rates available come from 2.4 mg semaglutide trials and pooled analyses, not from a dose-by-dose breakdown of Ozempic 0.5 to 2 mg.

SELECT randomized 17,604 adults with established cardiovascular disease and a BMI of 27 or more but no diabetes, with a mean follow-up of 39.8 months [6]. Gallbladder-related disorders occurred in 2.8% on semaglutide 2.4 mg versus 2.3% on placebo (p = 0.04), driven mainly by cholelithiasis at 1.4% versus 1.1%; cholecystitis was 0.6% in both groups [2].

Across nine randomized trials of once-weekly semaglutide in 11,641 people with overweight or obesity without diabetes and 10,479 controls, cholelithiasis had an odds ratio of 2.06 (p = 0.04) and gallbladder disorders 1.26 (p = 0.010) [3]. A meta-analysis of 21 trials covering 99,599 patients on GLP-1 receptor agonists found 26% more gallbladder disorders than with controls [4].

The only week-based schedule is the titration

Ozempic starts at 0.25 mg weekly for 4 weeks, moves to 0.5 mg, then to 1 mg and 2 mg only after at least 4 weeks at each previous dose, so reaching 2 mg takes at least 12 weeks under the labeled schedule [1]. The label's gallbladder warning does not single out any titration step, and the 40-week trial of 959 patients comparing 2 mg with 1 mg reported no new safety signals [1].

Frequently asked questions

How common are gallbladder problems on semaglutide?
The Ozempic label reports cholelithiasis in 1.5% of patients on 0.5 mg and 0.4% on 1 mg in placebo-controlled trials, and not in placebo-treated patients; it also warns that acute gallbladder disease can occur and says gallbladder studies are indicated if cholelithiasis or cholecystitis are suspected [1]. In SELECT, gallbladder-related disorders occurred in 2.8% on semaglutide 2.4 mg versus 2.3% on placebo [2].
Does 2 mg of Ozempic cause more gallbladder problems than 0.5 mg?
The Ozempic label gives cholelithiasis rates for 0.5 mg (1.5%) and 1 mg (0.4%) but none for 2 mg. The 40-week trial of 959 patients that compared 2 mg with 1 mg reported no new safety signals [1].
What does the Ozempic label say when gallstones are suspected?
The label states that if cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1]. Cholecystitis and cholecystectomy are also listed among postmarketing reports, where a frequency cannot be estimated [1].
Are gallbladder problems more common in teenagers on semaglutide?
In a 68-week trial of 201 adolescents aged 12 to under 18 with obesity, cholelithiasis occurred in 4% of those on semaglutide 2.4 mg versus 0% on placebo [7].
Is gallbladder disease a class effect of GLP-1 drugs?
A meta-analysis of 21 randomized trials covering 99,599 patients on GLP-1 receptor agonists, including semaglutide, dulaglutide and liraglutide, found 26% more gallbladder disorders than with controls [4].

References

  1. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
  2. Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring). 2025;33(3):452-462. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
  3. Kommu S, Berg RL. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024;25(9):e13792. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials
  4. Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025;86(20):1805-1819. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
  5. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Once-Weekly Semaglutide in Adults with Overweight or Obesity
  6. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
  7. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245-2257. Once-Weekly Semaglutide in Adolescents with Obesity
Evidence overview for Gallbladder Disease on Ozempic (Semaglutide 0.5-2 mg): Week-by-Week Timeline of What to Expect